| Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised … C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ... The lancet oncology 20 (6), 849-861, 2019 | 439 | 2019 |
| Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E–mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON … E Van Cutsem, S Huijberts, A Grothey, R Yaeger, PJ Cuyle, E Elez, ... Journal of clinical oncology 37 (17), 1460, 2019 | 226 | 2019 |
| Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease D Labaere, A Smismans, A Van Olmen, P Christiaens, G D’Haens, ... United European Gastroenterology Journal 2 (1), 30-37, 2014 | 172 | 2014 |
| DPYD genotyping to predict adverse events following treatment with fluorouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the … V Boige, M Vincent, P Alexandre, S Tejpar, S Landolfi, K Le Malicot, ... JAMA oncology 2 (5), 655-662, 2016 | 80 | 2016 |
| BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers. E Van Cutsem, PJ Cuyle, S Huijberts, R Yaeger, JHM Schellens, E Elez, ... Journal of Clinical Oncology 36 (4_suppl), 627-627, 2018 | 59 | 2018 |
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label … S Qin, M Chen, AL Cheng, AO Kaseb, M Kudo, HC Lee, AC Yopp, J Zhou, ... The Lancet 402 (10415), 1835-1847, 2023 | 54 | 2023 |
| Current and future biomarkers in the treatment of colorectal cancer PJ Cuyle, H Prenen Acta Clinica Belgica 72 (2), 103-115, 2017 | 51 | 2017 |
| Urea-splitting urinary tract infection contributing to hyperammonemic encephalopathy M Albersen, S Joniau, H Van Poppel, PJ Cuyle, DC Knockaert, ... Nature Clinical Practice Urology 4 (8), 455-458, 2007 | 49 | 2007 |
| Impact of endoscopy system, high definition, and virtual chromoendoscopy in daily routine colonoscopy: a randomized trial P Roelandt, I Demedts, H Willekens, T Bessissow, L Braeye, G Coremans, ... Endoscopy 51 (03), 237-243, 2019 | 30 | 2019 |
| BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib+ MEK inhibitor binimetinib+ anti–epidermal growth factor receptor antibody cetuximab for BRAFV600E … E Van Cutsem, P Cuyle, S Huijberts, J Schellens, E Elez, R Yaeger, ... Annals of Oncology 29, v109, 2018 | 24 | 2018 |
| Molecular detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA®GENE Helicobacter pylori assay B Van den Poel, S Gils, I Micalessi, S Carton, P Christiaens, PJ Cuyle, ... Acta Clinica Belgica 76 (3), 177-183, 2021 | 20 | 2021 |
| Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO)+ binimetinib (BINI)+ cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC). S Kopetz, A Grothey, R Yaeger, PJAR Cuyle, S Huijberts, JHM Schellens, ... Journal of Clinical Oncology 37 (4_suppl), 688-688, 2019 | 20 | 2019 |
| Molecular targeting of a BRAF mutation in pancreatic ductal adenocarcinoma: case report and literature review AK Seghers, PJ Cuyle, E Van Cutsem Targeted Oncology 15 (3), 407-410, 2020 | 19 | 2020 |
| Targeting DNA damage repair mechanisms in pancreas cancer L Perkhofer, T Golan, PJ Cuyle, T Matysiak-Budnik, JL Van Laethem, ... Cancers 13 (17), 4259, 2021 | 17 | 2021 |
| Buried bumper syndrome: single-step endoscopic management and replacement P Christiaens, P Bossuyt, PJ Cuyle, V Moons, A Van Olmen Gastrointestinal Endoscopy 80 (2), 336, 2014 | 17 | 2014 |
| Long-term follow-up in a patient with the dermato-neuro syndrome treated with high-dose melphalan, thalidomide, and intravenous immunoglobulins for more than 7 years T Devos, S Thiessen, PJ Cuyle, W Meersseman, M Delforge Annals of hematology 93, 1927-1928, 2014 | 13 | 2014 |
| BEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal … S Huijberts, JHM Schellens, E Elez, PJ Cuyle, E Van Cutsem, R Yaeger, ... Annals of Oncology 28, v175, 2017 | 10 | 2017 |
| Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study E Martinelli, C Cremolini, T Mazard, J Vidal, I Virchow, D Tougeron, ... ESMO open 7 (6), 100603, 2022 | 9 | 2022 |
| Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors PJ Cuyle, H Prenen Annals of Gastroenterology 31 (2), 140, 2018 | 9 | 2018 |
| Lanreotide in the prevention and management of high-output ileostomy after colorectal cancer surgery PJ Cuyle, A Engelen, V Moons, T Tollens, S Carton Journal of Drug Assessment 7 (1), 28-33, 2018 | 8 | 2018 |
